BUSINESS SEGMENT INFORMATION (Tables)

9 Months Ended

Sep. 30, 2016

Segment Reporting [Abstract]

Product Revenues [Table Text Block]

The composition of total revenues was as follows:

	Three Months Ended September 30,				Nine Months Ended September 30,
Dollars in Millions	2016		2015		2016		2015
Net product sales	$	4,492	$	3,552	$	12,888	$	10,183
Alliance revenues	402		496		1,229		2,003
Other revenues	28		21		67		87
Total Revenues	$	4,922	$	4,069	$	14,184	$	12,273

Product revenues were as follows:

	Three Months Ended September 30,				Nine Months Ended September 30,
Dollars in Millions	2016		2015		2016		2015
Oncology
Empliciti (elotuzumab)	$	41	$	—	$	103	$	—
Erbitux* (cetuximab)	—		167		—		501
Opdivo (nivolumab)	920		305		2,464		467
Sprycel (dasatinib)	472		411		1,330		1,191
Yervoy (ipilimumab)	285		240		789		861
Cardiovascular
Eliquis (apixaban)	884		466		2,395		1,258
Immunoscience
Orencia (abatacept)	572		484		1,640		1,345
Virology
Baraclude (entecavir)	306		320		896		1,003
Hepatitis C Franchise	379		402		1,352		1,145
Reyataz (atazanavir sulfate) Franchise	238		270		706		867
Sustiva (efavirenz) Franchise	275		333		819		940
Neuroscience
Abilify* (aripiprazole)	29		46		97		707
Mature Products and All Other	521		625		1,593		1,988
Total Revenues	$	4,922	$	4,069	$	14,184	$	12,273

* Indicates brand names of products which are trademarks not owned or wholly owned by BMS. Specific trademark ownership information is included at the end of this quarterly report on Form 10-Q.